Skip to main contentAI and Advanced
/
SOLARA · NSEMarket ticker unavailable · configure an authorised index feed
SO
NSE · Equity shares · Biotechnology & Drugs14.65 · 2.05%
Solara Active Pharma Sciences SOLARA
NSE:INR 730
BSE:INR 520.45
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for SOLARA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 715.35
Day rangeINR 669 — INR 730
52-week rangeINR 422 — INR 774
Volume7.30 L
Market cap2,516.29
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,368.98
Net Income (INR Cr)-7.41
Rev Growth (5 Year %)-3.27
Book Value180.17
EPS-0.34
Price/BV4.05Computed
Research path: Interpret Solara Active Pharma Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SOLARASolara Active Pharma Sciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,332.59 | 2,231.84 | 2,350.96 |
| Cash Equivalents | 4.48 | Not available | Not available |
| Other Liabilities Total | 53.47 | 59.19 | 54.09 |
| Accrued Expenses | 13.88 | 13.21 | 5.35 |
| Long Term Debt | 110.45 | 113.86 | 105.83 |
| Common Stock Total | 44.51 | 40.25 | 36 |
| Other Current Assets Total | 41.6 | 0.16 | 12.84 |
| Total Assets | 2,332.59 | 2,231.84 | 2,350.96 |
| Current Portof LT Debt/Capital Leases | 556.9 | 91.55 | 133.79 |
| Cash | 45.86 | 3.16 | 3.09 |
| Total Equity | 1,252.88 | 1,094.24 | 933.91 |
| Long Term Investments | 1.62 | 3.98 | 4.09 |
| Retained Earnings(Accumulated Deficit) | 1,208.37 | -312.33 | -315.86 |
| Total Common Shares Outstanding | 4.81 | 4.81 | 3.91 |
| Tangible Book Valueper Share Common Eq | 180.17 | 145.58 | 134.72 |
| Goodwill Net | 364.9 | 364.9 | 365.09 |
| Total Liabilities | 1,079.71 | 1,137.6 | 1,417.05 |
| Total Debt | 686.56 | 796.08 | 1,011.5 |
| Short Term Investments | 9.54 | 0.79 | 5.35 |
| Cashand Short Term Investments | 59.88 | 3.95 | 8.44 |
| Total Receivables Net | 438.75 | 381.03 | 397.01 |
| Accounts Receivable-Trade Net | 438.72 | 326.59 | 348.53 |
| Property/Plant/Equipment Total-Net | 1,055.2 | 1,076.47 | 1,114.22 |
| Minority Interest | 2.67 | 2.67 | 2.67 |
| Total Current Liabilities | 893.91 | 944.11 | 1,242.85 |
| Total Inventory | 317.87 | 327.36 | 371.04 |
| Accounts Payable | 273.9 | 248.62 | 313.01 |
| Other Currentliabilities Total | 49.23 | 17.83 | 30.43 |
| Total Long Term Debt | 129.66 | 131.63 | 117.44 |
| Intangibles Net | 22.2 | 29.8 | 42.56 |
| Other Long Term Assets Total | 23.94 | 16.75 | 15.83 |
| Note Receivable-Long Term | 6.63 | 11.21 | 8.42 |
| Total Current Assets | 858.1 | 728.73 | 800.75 |
| Capital Lease Obligations | 19.21 | 17.77 | 11.61 |
| Accumulated Depreciation Total | Not available | -596.72 | -515.47 |
| Other Equity Total | Not available | -2.34 | -2.26 |
| Prepaid Expenses | Not available | 16.23 | 11.42 |
| Additional Paid-In Capital | Not available | 1,368.66 | 1,216.03 |
| Property/Plant/Equipment Total-Gross | Not available | 1,393.14 | 1,373.32 |
| Notes Payable/Short Term Debt | Not available | 572.9 | 760.27 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %2.04
Margins
Operating Margin 12m5.93
Operating Margin 5y Avg-3.01
Net Profit Margin 12m-0.54
Net Profit Margin 5y-9.83
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio1.84
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk42.69
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,935.55 | 4.64 L | 38.4 | — |
| Divi's Laboratories | INR 7,363.65 | 1.95 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,972.05 | 1.68 L | 72.73 | — |
| Cipla | INR 1,406.45 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,120.35 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 41.93%
- FII
- 11.52%
- MF
- 0.95%
- Other
- 45.60%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Corporate actions
Events
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- annual General MeetingSecond & Final call of Rs.112.50/- per equity shares
- board MeetingsInter-alia, to consider 1. Making Second & Final Call on partly paid-up Equity Shares. 2. To fix the Record Date for the purpose of determining the eligible shareholders. 3. Other business matters.
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Solara Active Pharma Sciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SOLARA
- BSE Code
- 541540
Questions
Stock FAQ
What is the symbol and ISIN of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has the symbol SOLARA and ISIN - INE624Z01016.
What is the current price of Solara Active Pharma Sciences?
Solara Active Pharma Sciences is currently trading at INR 730.00.
What are the year high and year low of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a year high of INR 774.00 and a year low of INR 422.00.
What is the market capitalization of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a market capitalization of INR 2,516.29 crore.
What is the P/E ratio of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a P/E ratio of NA.
What is the dividend yield of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a dividend yield of 0.00%.
How is the financial performance of Solara Active Pharma Sciences based on revenue, net income, and EPS?
Solara Active Pharma Sciences has revenue of INR 1,368.98 crore, net income of INR -7.41 crore, and EPS of INR -0.34.
What is the book value of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a book value of INR 180.17.
What is the debt-to-equity ratio of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Solara Active Pharma Sciences?
Solara Active Pharma Sciences has a price-to-book ratio of 4.05 and a price-to-sales ratio of 1.84.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.